Stryker (NYSE:SYK) Cut to "Hold" at Wall Street Zen

Stryker (NYSE:SYK - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Friday.

A number of other research firms have also weighed in on SYK. BTIG Research set a $403.00 price objective on shares of Stryker and gave the company a "buy" rating in a research note on Monday, April 14th. Sanford C. Bernstein set a $450.00 price target on shares of Stryker in a research report on Monday, May 5th. Evercore ISI lowered their price target on shares of Stryker from $400.00 to $390.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Citigroup reiterated a "buy" rating and set a $455.00 target price (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Finally, JMP Securities reissued a "market perform" rating on shares of Stryker in a report on Monday, May 5th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, Stryker presently has an average rating of "Moderate Buy" and an average target price of $427.30.

Stryker Stock Performance

Shares of NYSE SYK traded up $1.05 during midday trading on Friday, hitting $384.15. The company's stock had a trading volume of 709,048 shares, compared to its average volume of 1,331,290. The stock has a fifty day moving average price of $370.10 and a 200 day moving average price of $376.03. The firm has a market capitalization of $146.63 billion, a price-to-earnings ratio of 49.50, a P/E/G ratio of 2.93 and a beta of 0.93. Stryker has a one year low of $314.93 and a one year high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the company posted $2.50 EPS. On average, research analysts forecast that Stryker will post 13.47 EPS for the current fiscal year.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director now owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.90% of the company's stock.

Institutional Trading of Stryker

Several large investors have recently made changes to their positions in SYK. Kohmann Bosshard Financial Services LLC acquired a new stake in Stryker during the fourth quarter valued at $25,000. Capital A Wealth Management LLC acquired a new stake in shares of Stryker in the fourth quarter valued at about $26,000. Rakuten Securities Inc. boosted its holdings in shares of Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after purchasing an additional 68 shares during the last quarter. Centricity Wealth Management LLC acquired a new position in shares of Stryker during the 4th quarter valued at about $30,000. Finally, Goodman Advisory Group LLC purchased a new stake in shares of Stryker during the 1st quarter valued at approximately $32,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.